TY - JOUR AU - Alves, G. AU - Forsaa, E. B. AU - Pedersen, K. F. AU - Dreetz Gjerstad, M. AU - Larsen, J. P. PY - 2008 DA - 2008// TI - Epidemiology of Parkinson's disease JO - J Neurol VL - 255 UR - https://doi.org/10.1007/s00415-008-5004-3 DO - 10.1007/s00415-008-5004-3 ID - Alves2008 ER - TY - JOUR AU - Grosset, D. AU - Taurah, L. AU - Burn, D. J. AU - MacMahon, D. AU - Forbes, A. AU - Turner, K. AU - Bowron, A. AU - Walker, R. AU - Findley, L. AU - Foster, O. PY - 2007 DA - 2007// TI - A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis JO - J Neurol Neurosurg Psychiatry VL - 78 UR - https://doi.org/10.1136/jnnp.2006.098327 DO - 10.1136/jnnp.2006.098327 ID - Grosset2007 ER - TY - JOUR AU - Schapira, A. H. AU - Obeso, J. PY - 2006 DA - 2006// TI - Timing of treatment initiation in Parkinson's disease: a need for reappraisal? JO - Ann Neurol VL - 59 UR - https://doi.org/10.1002/ana.20789 DO - 10.1002/ana.20789 ID - Schapira2006 ER - TY - JOUR PY - 1993 DA - 1993// TI - Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease JO - N Engl J Med VL - 328 UR - https://doi.org/10.1056/NEJM199301213280305 DO - 10.1056/NEJM199301213280305 ID - ref4 ER - TY - JOUR PY - 2002 DA - 2002// TI - A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study JO - Arch Neurol VL - 59 UR - https://doi.org/10.1001/archneur.59.12.1937 DO - 10.1001/archneur.59.12.1937 ID - ref5 ER - TY - JOUR PY - 2004 DA - 2004// TI - A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease JO - Arch Neurol VL - 61 UR - https://doi.org/10.1001/archneur.61.4.561 DO - 10.1001/archneur.61.4.561 ID - ref6 ER - TY - JOUR AU - Olanow, C. W. AU - Rascol, O. AU - Hauser, R. AU - Feigin, P. D. AU - Jankovic, J. AU - Lang, A. AU - Langston, W. AU - Melamed, E. AU - Poewe, W. AU - Stocchi, F. PY - 2009 DA - 2009// TI - A double-blind, delayed-start trial of rasagiline in Parkinson's disease JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0809335 DO - 10.1056/NEJMoa0809335 ID - Olanow2009 ER - TY - JOUR AU - Allain, H. AU - Pollak, P. AU - Neukirch, H. C. PY - 1993 DA - 1993// TI - Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial JO - Mov Disord VL - 8 UR - https://doi.org/10.1002/mds.870080508 DO - 10.1002/mds.870080508 ID - Allain1993 ER - TY - JOUR AU - Palhagen, S. AU - Heinonen, E. H. AU - Hagglund, J. AU - Kaugesaar, T. AU - Kontants, H. AU - Maki-Ikola, O. AU - Palm, R. AU - Turunen, J. PY - 1998 DA - 1998// TI - Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group JO - Neurology VL - 51 UR - https://doi.org/10.1212/WNL.51.2.520 DO - 10.1212/WNL.51.2.520 ID - Palhagen1998 ER - TY - JOUR AU - Schrag, A. AU - Sampaio, C. AU - Counsell, N. AU - Poewe, W. PY - 2006 DA - 2006// TI - Minimal clinically important change on the unified Parkinson's disease rating scale JO - Mov Disord VL - 21 UR - https://doi.org/10.1002/mds.20914 DO - 10.1002/mds.20914 ID - Schrag2006 ER - TY - JOUR PY - 1997 DA - 1997// TI - Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study JO - Jama VL - 278 UR - https://doi.org/10.1001/jama.1997.03550020057038 DO - 10.1001/jama.1997.03550020057038 ID - ref11 ER - TY - JOUR AU - Adler, C. H. AU - Sethi, K. D. AU - Hauser, R. A. AU - Davis, T. L. AU - Hammerstad, J. P. AU - Bertoni, J. AU - Taylor, R. L. AU - Sanchez-Ramos, J. AU - O'Brien, C. F. PY - 1997 DA - 1997// TI - Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group JO - Neurology VL - 49 UR - https://doi.org/10.1212/WNL.49.2.393 DO - 10.1212/WNL.49.2.393 ID - Adler1997 ER - TY - JOUR AU - Shannon, K. M. AU - Bennett, J. P. AU - Friedman, J. H. PY - 1997 DA - 1997// TI - Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group JO - Neurology VL - 49 UR - https://doi.org/10.1212/WNL.49.3.724 DO - 10.1212/WNL.49.3.724 ID - Shannon1997 ER - TY - JOUR PY - 2003 DA - 2003// TI - A controlled trial of rotigotine monotherapy in early Parkinson's disease JO - Arch Neurol VL - 60 UR - https://doi.org/10.1001/archneur.60.12.1721 DO - 10.1001/archneur.60.12.1721 ID - ref14 ER - TY - JOUR AU - Fahn, S. AU - Oakes, D. AU - Shoulson, I. AU - Kieburtz, K. AU - Rudolph, A. AU - Lang, A. AU - Olanow, C. W. AU - Tanner, C. AU - Marek, K. PY - 2004 DA - 2004// TI - Levodopa and the progression of Parkinson's disease JO - N Engl J Med VL - 351 UR - https://doi.org/10.1056/NEJMoa033447 DO - 10.1056/NEJMoa033447 ID - Fahn2004 ER - TY - JOUR AU - Hauser, R. A. AU - Auinger, P. AU - Oakes, D. PY - 2009 DA - 2009// TI - Levodopa response in early Parkinson's disease JO - Mov Disord VL - 24 ID - Hauser2009 ER - TY - JOUR PY - 1996 DA - 1996// TI - Effect of lazabemide on the progression of disability in early Parkinson's disease JO - Ann Neurol VL - 40 UR - https://doi.org/10.1002/ana.410400116 DO - 10.1002/ana.410400116 ID - ref17 ER - TY - JOUR AU - Tetrud, J. W. AU - Langston, J. W. PY - 1989 DA - 1989// TI - The effect of deprenyl (selegiline) on the natural history of Parkinson's disease JO - Science VL - 245 UR - https://doi.org/10.1126/science.2502843 DO - 10.1126/science.2502843 ID - Tetrud1989 ER - TY - JOUR AU - Myllyla, V. V. AU - Sotaniemi, K. A. AU - Vuorinen, J. A. AU - Heinonen, E. H. PY - 1992 DA - 1992// TI - Selegiline as initial treatment in de novo parkinsonian patients JO - Neurology VL - 42 UR - https://doi.org/10.1212/WNL.42.2.339 DO - 10.1212/WNL.42.2.339 ID - Myllyla1992 ER - TY - JOUR AU - Ives, N. J. AU - Stowe, R. L. AU - Marro, J. AU - Counsell, C. AU - Macleod, A. AU - Clarke, C. E. AU - Gray, R. AU - Wheatley, K. PY - 2004 DA - 2004// TI - Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients JO - BMJ VL - 329 UR - https://doi.org/10.1136/bmj.38184.606169.AE DO - 10.1136/bmj.38184.606169.AE ID - Ives2004 ER - TY - JOUR AU - Myllyla, V. V. AU - Sotaniemi, K. A. AU - Hakulinen, P. AU - Maki-Ikola, O. AU - Heinonen, E. H. PY - 1997 DA - 1997// TI - Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study JO - Acta Neurol Scand VL - 95 UR - https://doi.org/10.1111/j.1600-0404.1997.tb00101.x DO - 10.1111/j.1600-0404.1997.tb00101.x ID - Myllyla1997 ER - TY - JOUR AU - Caraceni, T. AU - Musicco, M. PY - 2001 DA - 2001// TI - Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study JO - Parkinsonism Relat Disord VL - 7 UR - https://doi.org/10.1016/S1353-8020(00)00023-7 DO - 10.1016/S1353-8020(00)00023-7 ID - Caraceni2001 ER - TY - JOUR AU - Rascol, O. AU - Brooks, D. J. AU - Korczyn, A. D. AU - De, D. P. P. AU - Clarke, C. E. AU - Lang, A. E. PY - 2000 DA - 2000// TI - A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa JO - N Engl J Med VL - 342 UR - https://doi.org/10.1056/NEJM200005183422004 DO - 10.1056/NEJM200005183422004 ID - Rascol2000 ER - TY - JOUR PY - 2009 DA - 2009// TI - Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease JO - Arch Neurol VL - 66 UR - https://doi.org/10.1001/archneurol.2009.32 DO - 10.1001/archneurol.2009.32 ID - ref24 ER - TY - JOUR AU - Holloway, R. G. AU - Shoulson, I. AU - Fahn, S. AU - Kieburtz, K. AU - Lang, A. AU - Marek, K. AU - McDermott, M. AU - Seibyl, J. AU - Weiner, W. AU - Musch, B. PY - 2004 DA - 2004// TI - Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial JO - Arch Neurol VL - 61 ID - Holloway2004 ER - TY - JOUR AU - Poewe, W. H. AU - Lees, A. J. AU - Stern, G. M. PY - 1986 DA - 1986// TI - Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study JO - Neurology VL - 36 UR - https://doi.org/10.1212/WNL.36.11.1528 DO - 10.1212/WNL.36.11.1528 ID - Poewe1986 ER - TY - JOUR AU - Martin, W. R. AU - Sloan, J. W. AU - Sapira, J. D. AU - Jasinski, D. R. PY - 1971 DA - 1971// TI - Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man JO - Clin Pharmacol Ther VL - 12 UR - https://doi.org/10.1002/cpt1971122part1245 DO - 10.1002/cpt1971122part1245 ID - Martin1971 ER - TY - JOUR AU - Churchyard, A. AU - Mathias, C. J. AU - Boonkongchuen, P. AU - Lees, A. J. PY - 1997 DA - 1997// TI - Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease JO - J Neurol Neurosurg Psychiatry VL - 63 UR - https://doi.org/10.1136/jnnp.63.2.228 DO - 10.1136/jnnp.63.2.228 ID - Churchyard1997 ER - TY - JOUR AU - Yasar, S. AU - Goldberg, J. P. AU - Goldberg, S. R. PY - 1996 DA - 1996// TI - Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research JO - J Neural Transm Suppl VL - 48 ID - Yasar1996 ER - TY - JOUR AU - Yasar, S. AU - Justinova, Z. AU - Lee, S. H. AU - Stefanski, R. AU - Goldberg, S. R. AU - Tanda, G. PY - 2006 DA - 2006// TI - Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl] JO - J Pharmacol Exp Ther VL - 317 UR - https://doi.org/10.1124/jpet.105.096263 DO - 10.1124/jpet.105.096263 ID - Yasar2006 ER - TY - JOUR AU - Gill, J. R. AU - Masson, D. T. AU - Bartter, F. C. PY - 1967 DA - 1967// TI - Effects of hydroxyamphetamine (paredrine) on the function of the sympathetic nervous system in normotensive subjects JO - J Pharmacol Exp Ther VL - 155 ID - Gill1967 ER - TY - JOUR AU - Schulz, R. AU - Antonin, K. H. AU - Hoffmann, E. AU - Jedrychowski, M. AU - Nilsson, E. AU - Schick, C. AU - Bieck, P. R. PY - 1989 DA - 1989// TI - Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline JO - Clin Pharmacol Ther VL - 46 UR - https://doi.org/10.1038/clpt.1989.181 DO - 10.1038/clpt.1989.181 ID - Schulz1989 ER - TY - JOUR AU - Mantle, T. J. AU - Tipton, K. F. AU - Garrett, N. J. PY - 1976 DA - 1976// TI - Inhibition of monoamine oxidase by amphetamine and related compounds JO - Biochem Pharmacol VL - 25 UR - https://doi.org/10.1016/0006-2952(76)90432-9 DO - 10.1016/0006-2952(76)90432-9 ID - Mantle1976 ER - TY - JOUR AU - Suzuki, O. AU - Hattori, H. AU - Asano, M. AU - Oya, M. AU - Katsumata, Y. PY - 1980 DA - 1980// TI - Inhibition of monoamine oxidase by d-methamphetamine JO - Biochem Pharmacol VL - 29 UR - https://doi.org/10.1016/0006-2952(80)90493-1 DO - 10.1016/0006-2952(80)90493-1 ID - Suzuki1980 ER - TY - JOUR AU - Chen, J. J. AU - Swope, D. M. AU - Dashtipour, K. PY - 2007 DA - 2007// TI - Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease JO - Clin Ther VL - 29 UR - https://doi.org/10.1016/j.clinthera.2007.09.021 DO - 10.1016/j.clinthera.2007.09.021 ID - Chen2007 ER - TY - JOUR AU - Lees, A. J. PY - 1995 DA - 1995// TI - Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom JO - BMJ VL - 311 UR - https://doi.org/10.1136/bmj.311.7020.1602 DO - 10.1136/bmj.311.7020.1602 ID - Lees1995 ER - TY - JOUR AU - Ben-Shlomo, Y. AU - Churchyard, A. AU - Head, J. AU - Hurwitz, B. AU - Overstall, P. AU - Ockelford, J. AU - Lees, A. J. PY - 1998 DA - 1998// TI - Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry JO - BMJ VL - 316 UR - https://doi.org/10.1136/bmj.316.7139.1191 DO - 10.1136/bmj.316.7139.1191 ID - Ben-Shlomo1998 ER - TY - JOUR AU - Löhle, M. AU - Storch, A. PY - 2008 DA - 2008// TI - Orally disintegrating selegiline for the treatment of Parkinson's disease JO - Expert Opin Pharmacother VL - 9 UR - https://doi.org/10.1517/14656566.9.16.2881 DO - 10.1517/14656566.9.16.2881 ID - Löhle2008 ER - TY - JOUR AU - Rascol, O. AU - Brooks, D. J. AU - Melamed, E. AU - Oertel, W. AU - Poewe, W. AU - Stocchi, F. AU - Tolosa, E. PY - 2005 DA - 2005// TI - Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial JO - Lancet VL - 365 UR - https://doi.org/10.1016/S0140-6736(05)71083-7 DO - 10.1016/S0140-6736(05)71083-7 ID - Rascol2005 ER - TY - JOUR PY - 2005 DA - 2005// TI - A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study JO - Arch Neurol VL - 62 UR - https://doi.org/10.1001/archneur.62.2.241 DO - 10.1001/archneur.62.2.241 ID - ref40 ER - TY - JOUR AU - Goren, T. AU - Adar, L. AU - Sasson, N. AU - Weiss, Y. M. PY - 2010 DA - 2010// TI - Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline JO - J Clin Pharmacol VL - 50 UR - https://doi.org/10.1177/0091270010369674 DO - 10.1177/0091270010369674 ID - Goren2010 ER - TY - JOUR AU - Perez-Lloret, S. AU - Rascol, O. PY - 2011 DA - 2011// TI - Safety of rasagiline for the treatment of Parkinson's disease JO - Expert Opin Drug Saf VL - 10 UR - https://doi.org/10.1517/14740338.2011.573784 DO - 10.1517/14740338.2011.573784 ID - Perez-Lloret2011 ER - TY - JOUR AU - Richard, I. H. AU - Kurlan, R. AU - Tanner, C. AU - Factor, S. AU - Hubble, J. AU - Suchowersky, O. AU - Waters, C. PY - 1997 DA - 1997// TI - Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group JO - Neurology VL - 48 UR - https://doi.org/10.1212/WNL.48.4.1070 DO - 10.1212/WNL.48.4.1070 ID - Richard1997 ER - TY - JOUR AU - Leopold, N. A. AU - Polansky, M. AU - Hurka, M. R. PY - 2004 DA - 2004// TI - Drug adherence in Parkinson's disease JO - Mov Disord VL - 19 UR - https://doi.org/10.1002/mds.20041 DO - 10.1002/mds.20041 ID - Leopold2004 ER - TY - JOUR AU - Grosset, K. A. AU - Bone, I. AU - Grosset, D. G. PY - 2005 DA - 2005// TI - Suboptimal medication adherence in Parkinson's disease JO - Mov Disord VL - 20 UR - https://doi.org/10.1002/mds.20602 DO - 10.1002/mds.20602 ID - Grosset2005 ER - TY - JOUR AU - Grosset, D. AU - Antonini, A. AU - Canesi, M. AU - Pezzoli, G. AU - Lees, A. AU - Shaw, K. AU - Cubo, E. AU - Martinez-Martin, P. AU - Rascol, O. AU - Negre-Pages, L. PY - 2009 DA - 2009// TI - Adherence to antiparkinson medication in a multicenter European study JO - Mov Disord VL - 24 UR - https://doi.org/10.1002/mds.22112 DO - 10.1002/mds.22112 ID - Grosset2009 ER - TY - JOUR AU - Stocchi, F. PY - 2009 DA - 2009// TI - The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease JO - Parkinsonism Relat Disord VL - 15 UR - https://doi.org/10.1016/S1353-8020(09)70005-7 DO - 10.1016/S1353-8020(09)70005-7 ID - Stocchi2009 ER - TY - JOUR AU - Nilsson, H. AU - Ekberg, O. AU - Olsson, R. AU - Hindfelt, B. PY - 1996 DA - 1996// TI - Quantitative assessment of oral and pharyngeal function in Parkinson's disease JO - Dysphagia VL - 11 UR - https://doi.org/10.1007/BF00417905 DO - 10.1007/BF00417905 ID - Nilsson1996 ER - TY - JOUR AU - Potulska, A. AU - Friedman, A. AU - Krolicki, L. AU - Spychala, A. PY - 2003 DA - 2003// TI - Swallowing disorders in Parkinson's disease JO - Parkinsonism Relat Disord VL - 9 UR - https://doi.org/10.1016/S1353-8020(03)00045-2 DO - 10.1016/S1353-8020(03)00045-2 ID - Potulska2003 ER - TY - STD TI - Virely P, Yarwood R: Zydis: a novel, fast dissolving dosage form. Manuf Chem. 1990, 36-37. 61 ID - ref50 ER - TY - JOUR AU - Clarke, A. AU - Johnson, E. S. AU - Mallard, N. AU - Corn, T. H. AU - Johnston, A. AU - Boyce, M. AU - Warrington, S. AU - MacMahon, D. G. PY - 2003 DA - 2003// TI - A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition JO - J Neural Transm VL - 110 UR - https://doi.org/10.1007/s00702-003-0042-6 DO - 10.1007/s00702-003-0042-6 ID - Clarke2003 ER - TY - JOUR AU - Löhle, M. AU - Reichmann, H. PY - 2010 DA - 2010// TI - Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough JO - J Neurol Sci VL - 289 UR - https://doi.org/10.1016/j.jns.2009.08.025 DO - 10.1016/j.jns.2009.08.025 ID - Löhle2010 ER - TY - JOUR AU - Hely, M. A. AU - Morris, J. G. AU - Reid, W. G. AU - Trafficante, R. PY - 2005 DA - 2005// TI - Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years JO - Mov Disord VL - 20 UR - https://doi.org/10.1002/mds.20324 DO - 10.1002/mds.20324 ID - Hely2005 ER - TY - JOUR AU - Olanow, C. W. PY - 2004 DA - 2004// TI - The scientific basis for the current treatment of Parkinson's disease JO - Annu Rev Med VL - 55 UR - https://doi.org/10.1146/annurev.med.55.091902.104422 DO - 10.1146/annurev.med.55.091902.104422 ID - Olanow2004 ER - TY - JOUR AU - Cohen, G. AU - Pasik, P. AU - Cohen, B. AU - Leist, A. AU - Mytilineou, C. AU - Yahr, M. D. PY - 1984 DA - 1984// TI - Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys JO - Eur J Pharmacol VL - 106 UR - https://doi.org/10.1016/0014-2999(84)90700-3 DO - 10.1016/0014-2999(84)90700-3 ID - Cohen1984 ER - TY - JOUR AU - Heikkila, R. E. AU - Manzino, L. AU - Cabbat, F. S. AU - Duvoisin, R. C. PY - 1984 DA - 1984// TI - Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors JO - Nature VL - 311 UR - https://doi.org/10.1038/311467a0 DO - 10.1038/311467a0 ID - Heikkila1984 ER - TY - JOUR AU - Mytilineou, C. AU - Radcliffe, P. AU - Leonardi, E. K. AU - Werner, P. AU - Olanow, C. W. PY - 1997 DA - 1997// TI - L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro JO - J Neurochem VL - 68 UR - https://doi.org/10.1046/j.1471-4159.1997.68010033.x DO - 10.1046/j.1471-4159.1997.68010033.x ID - Mytilineou1997 ER - TY - JOUR AU - Mytilineou, C. AU - Radcliffe, P. M. AU - Olanow, C. W. PY - 1997 DA - 1997// TI - L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro JO - J Neurochem VL - 68 UR - https://doi.org/10.1046/j.1471-4159.1997.68010434.x DO - 10.1046/j.1471-4159.1997.68010434.x ID - Mytilineou1997 ER - TY - JOUR AU - Mytilineou, C. AU - Leonardi, E. K. AU - Radcliffe, P. AU - Heinonen, E. H. AU - Han, S. K. AU - Werner, P. AU - Cohen, G. AU - Olanow, C. W. PY - 1998 DA - 1998// TI - Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion JO - J Pharmacol Exp Ther VL - 284 ID - Mytilineou1998 ER - TY - JOUR AU - Finberg, J. P. AU - Takeshima, T. AU - Johnston, J. M. AU - Commissiong, J. W. PY - 1998 DA - 1998// TI - Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor JO - Neuroreport VL - 9 UR - https://doi.org/10.1097/00001756-199803090-00026 DO - 10.1097/00001756-199803090-00026 ID - Finberg1998 ER - TY - JOUR AU - Goggi, J. AU - Theofilopoulos, S. AU - Riaz, S. S. AU - Jauniaux, E. AU - Stern, G. M. AU - Bradford, H. F. PY - 2000 DA - 2000// TI - The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture JO - Neuroreport VL - 11 UR - https://doi.org/10.1097/00001756-200012180-00007 DO - 10.1097/00001756-200012180-00007 ID - Goggi2000 ER - TY - STD TI - Maruyama W, Akao Y, Youdim MB, Naoi M: Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl. 2000, 171-186. 60 ID - ref62 ER - TY - JOUR AU - Naoi, M. AU - Maruyama, W. AU - Youdim, M. B. AU - Yu, P. AU - Boulton, A. A. PY - 2003 DA - 2003// TI - Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase JO - Inflammopharmacology VL - 11 UR - https://doi.org/10.1163/156856003765764344 DO - 10.1163/156856003765764344 ID - Naoi2003 ER - TY - JOUR AU - Blandini, F. AU - Armentero, M. T. AU - Fancellu, R. AU - Blaugrund, E. AU - Nappi, G. PY - 2004 DA - 2004// TI - Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease JO - Exp Neurol VL - 187 UR - https://doi.org/10.1016/j.expneurol.2004.03.005 DO - 10.1016/j.expneurol.2004.03.005 ID - Blandini2004 ER - TY - JOUR AU - Kupsch, A. AU - Sautter, J. AU - Gotz, M. E. AU - Breithaupt, W. AU - Schwarz, J. AU - Youdim, M. B. AU - Riederer, P. AU - Gerlach, M. AU - Oertel, W. H. PY - 2001 DA - 2001// TI - Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline JO - J Neural Transm VL - 108 UR - https://doi.org/10.1007/s007020170018 DO - 10.1007/s007020170018 ID - Kupsch2001 ER - TY - JOUR PY - 1989 DA - 1989// TI - Effect of deprenyl on the progression of disability in early Parkinson's disease JO - N Engl J Med VL - 321 UR - https://doi.org/10.1056/NEJM198911163212004 DO - 10.1056/NEJM198911163212004 ID - ref66 ER - TY - JOUR PY - 1998 DA - 1998// TI - Mortality in DATATOP: a multicenter trial in early Parkinson's disease JO - Ann Neurol VL - 43 UR - https://doi.org/10.1002/ana.410430309 DO - 10.1002/ana.410430309 ID - ref67 ER - TY - JOUR AU - Hauser, R. A. AU - Lew, M. F. AU - Hurtig, H. I. AU - Ondo, W. G. AU - Wojcieszek, J. AU - Fitzer-Attas, C. J. PY - 2009 DA - 2009// TI - Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease JO - Mov Disord VL - 24 UR - https://doi.org/10.1002/mds.22402 DO - 10.1002/mds.22402 ID - Hauser2009 ER - TY - JOUR AU - Clarke, C. E. PY - 2008 DA - 2008// TI - Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? JO - Mov Disord VL - 23 UR - https://doi.org/10.1002/mds.21918 DO - 10.1002/mds.21918 ID - Clarke2008 ER - TY - JOUR AU - Parkinson, S. G. PY - 2002 DA - 2002// TI - Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression JO - Jama VL - 287 UR - https://doi.org/10.1001/jama.287.13.1653 DO - 10.1001/jama.287.13.1653 ID - Parkinson2002 ER - TY - JOUR AU - Whone, A. L. AU - Watts, R. L. AU - Stoessl, A. J. AU - Davis, M. AU - Reske, S. AU - Nahmias, C. AU - Lang, A. E. AU - Rascol, O. AU - Ribeiro, M. J. AU - Remy, P. PY - 2003 DA - 2003// TI - Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study JO - Ann Neurol VL - 54 UR - https://doi.org/10.1002/ana.10609 DO - 10.1002/ana.10609 ID - Whone2003 ER - TY - JOUR AU - Ravina, B. AU - Eidelberg, D. AU - Ahlskog, J. E. AU - Albin, R. L. AU - Brooks, D. J. AU - Carbon, M. AU - Dhawan, V. AU - Feigin, A. AU - Fahn, S. AU - Guttman, M. PY - 2005 DA - 2005// TI - The role of radiotracer imaging in Parkinson disease JO - Neurology VL - 64 UR - https://doi.org/10.1212/01.WNL.0000149403.14458.7F DO - 10.1212/01.WNL.0000149403.14458.7F ID - Ravina2005 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/11/112/prepub UR - http://www.biomedcentral.com/1471-2377/11/112/prepub ID - ref73 ER -